scholarly journals Overexpression of SOX2 Is Associated with Better Overall Survival in Squamous Cell Lung Cancer Patients Treated with Adjuvant Radiotherapy

2016 ◽  
Vol 48 (2) ◽  
pp. 473-482 ◽  
Author(s):  
Hong In Yoon ◽  
Kyu Hyun Park ◽  
Eun-Jung Lee ◽  
Ki Chang Keum ◽  
Chang Geol Lee ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Cancer Patients ◽  
Squamous Cell ◽  
Cell Lung Cancer ◽  
Adjuvant Radiotherapy ◽  
Squamous Cell Lung Cancer ◽  
Lung Cancer Patients

scholarly journals Postoperative chemoradiotherapy is superior to postoperative chemotherapy alone in squamous cell lung cancer patients with limited N2 lymph node metastasis

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Liyu Su ◽  
Mingqiu Chen ◽  
Huiyan Su ◽  
Yaqing Dai ◽  
Shaoxing Chen ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Cancer Patients ◽  
Squamous Cell ◽  
Cell Lung Cancer ◽  
Postoperative Chemotherapy ◽  
Squamous Cell Lung Cancer ◽  
Lung Cancer Patients ◽  
Node Metastasis

Abstract Background The aim of the present study was to assess the efficacy of postoperative chemoradiotherapy (POCRT) following surgery in non-small-cell lung cancer patients with N2 lymph node metastasis (N2-NSCLC). Methods The clinical data of patients with N2-NSCLC treated with POCRT or postoperative chemotherapy (pCT) alone were retrospectively collected and reviewed. The overall survival (OS) rates were analyzed utilizing the Kaplan-Meier method and compared by the log-rank test. Cox regression analysis was used to determine factors significantly associated with survival. Propensity score matching (PSM) analysis was used to compensate for differences in baseline characteristics and OS was compared after matching. Results Between 2004 and 2014, a total of 175 patients fulfilled the inclusion criteria, 60 of whom were treated with POCRT, while 115 were administered pCT. The 1, 3 and 5-year OS rates in the POCRT and pCT groups were 98.3 vs. 86.1%, 71.7 vs. 53.0% and 45.7 vs. 39.0%, respectively (P = 0.019). Compared with pCT, POCRT improved OS in patients with squamous cell subtype (P = 0.010), no lymphovascular invasion (P = 0.006), pN2a (P = 0.006) or total number of metastatic lymph nodes ≤7 (P = 0.016). After PSM, these survival differences between POCRT and pCT remained significant in patients with squamous cell lung cancer (P = 0.010). Conclusions POCRT following complete resection may be beneficial for patients with squamous cell lung cancer, particularly those with limited nodal involvement.

The Clinical Value of Cyfra 21-1 Estimation for Lung Cancer Patients

1996 ◽  
Vol 11 (3) ◽  
pp. 172-177 ◽  
Author(s):  
M. Szturmowicz ◽  
A. Sakowicz ◽  
P. Rudzinski ◽  
J. Zych ◽  
E. Wiatr ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Squamous Cell ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Squamous Cell Lung Cancer ◽  
Cytokeratin 19 ◽  
Small Cell Lung ◽  
Lung Cancer Patients

Cytokeratin-19, one of the cytoskeletal proteins, is expressed both in bronchial epithelium and in lung cancer cells. The aim of our study was to establish the value of serum cytokeratin-19 soluble fragment (Cyfra 21-1) measurement in lung cancer patients. Cyfra 21-1 levels were estimated in 35 patients (pts) with benign lung diseases and in 116 lung cancer patients: 55 pts with squamous cell lung cancer, 38 pts with small cell lung cancer and 23 pts with adenocarcinoma. The cutoff level was set at 4 ng/ml with a specificity of 94% and a sensitivity of 40%. Elevated Cyfra 21-1 values were found in 44% of squamous cell lung cancer, 39% of adenocarcinoma and 34% of small cell lung cancer pts (the difference was not significant). In squamous cell lung cancer and in adenocarcinoma elevated Cyfra 21-1 values were observed more often in patients with advanced disease than in patients with limited disease. There was no significant correlation between the initial Cyfra 21-1 level and the response to chemotherapy. Cyfra 21-1 was hot a prognostic indicator, although in operable squamous cell lung cancer the proportion of survivors in the second year of observation was higher among the patients with normal preoperative Cyfra 21-1 levels.

Clinical characteristics and natural history of patients with squamous cell lung carcinoma with FGFR1 amplification.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 1533-1533
Author(s):  
Marc Christiaan Allardt Bos ◽  
Masyar Gardizi ◽  
Lukas Carl Heukamp ◽  
Hans-Ulrich Schildhaus ◽  
Lucia Nogova ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Natural History ◽  
Cancer Patients ◽  
Squamous Cell ◽  
Cell Lung Cancer ◽  
Clinical Characteristics ◽  
Squamous Cell Lung Cancer ◽  
Molecular Screening ◽  
Lung Cancer Patients ◽  
History Of

1533 Background: FGFR1 amplifications have been described as a promising oncogenic target in squamous cell lung cancer. Here we aimed at describing the clinical characteristics and natural history of FGFR1amplified squamous cell lung cancer patients. Methods: From 01/2011 to 01/2012 we screened 553 squamous cell lung cancer patients in our Network for Molecular Screening of Lung Cancer for the presence of FGFR1 amplifications by FISH analysis in accordance with the local ethics committee. FGFR1 was defined as amplified if the ratio of FGFR1 copies to centromeric copies was above 2 or if more than 50% of tumor cells showed 5 copies or if more than 15% of tumor cells demonstrated clusters of FGFR1. Clinical data were collected by extracting information from medical records, the local cancer registry and by questioning treating physicians and patients. Results: FGFR1FISH analysis could be performed in 95% of the cases and was amplified in 16%. Of the amplified cases 75 % were male and 25% female without significant enrichment for male or female. The median age of the patients at diagnosis was 67 yrs (range 46 - 82). Stage at presentation was: 16% I; 17.3% II; 26.7% IIIa, 40% IIIb/IV. 97,3% of the patients were former or active smokers with a median of 40 pack years. The median progression free survival of patients with stage IIIb/IV disease was 11 months (95% CI 8-14; n=14). The median overall survival was not yet reached after a median follow-up time of 14 months (95% CI 11 - 17; n=24). We further screened for co-existing genetic lesions such as mutations in EGFR, BRAF, KRAS, PIK3CA as well as translocations of ALK and amplifications of ERBB2. Two patients demonstrated co-occurring PIK3CA mutations and one a BRAFmutation. Conclusions: Screening for FGFR1 is feasible under routine clinical conditions. By implementation of a regional molecular screening network the ability to screen for FGFR1 amplification was successfully expanded to non-academic centers and private practices. FGFR1 amplifications in squamous cell cancer of the lung are frequent (16%) and associated with smoking history. Screening for FGFR1 might pave the way for the application of new FGFR1 directed targeted drugs in squamous cell lung cancer.

scholarly journals Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors

2015 ◽  
Vol 10 (9) ◽  
pp. 1341-1348 ◽  
Author(s):  
Sara Pilotto ◽  
Isabella Sperduti ◽  
Silvia Novello ◽  
Umberto Peretti ◽  
Michele Milella ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Risk Stratification ◽  
Cancer Patients ◽  
Squamous Cell ◽  
Cell Lung Cancer ◽  
Squamous Cell Lung Cancer ◽  
Lung Cancer Patients ◽  
Risk Stratification Model
Sign in / Sign up

Export Citation Format

Share Document